AmCham Abu Dhabi member Mubadala Investment Company, through its wholly owned life sciences company Mubadala Bio, has announced a strategic collaboration with U.S.
pharmaceutical company Eli Lilly and Company to advance the UAE’s life sciences sector.

Announced at the Abu Dhabi Future Health Summit 2026, the partnership will establish local packaging and logistics capabilities for Lilly’s GLP-1 medicines, including Mounjaro and Foundayo, strengthening pharmaceutical supply chains and expanding access to innovative treatments.

The collaboration brings together Lilly’s global pharmaceutical expertise and Mubadala Bio’s integrated life sciences capabilities. Operations will be anchored at a 125,000-square-meter location in KEZAD, Abu Dhabi, with packaging and warehousing facilities serving regional and international markets.

The agreement reflects the growing depth of U.S.–UAE cooperation in healthcare and the role of international partnerships in positioning Abu Dhabi as a global life sciences hub.

The collaboration also illustrates the connections at the core of AmCham Abu Dhabi’s mission. Through a member network spanning healthcare, investment, technology and other sectors, the Chamber supports partnerships between UAE institutions and U.S. companies that contribute to innovation, economic diversification and long-term growth in the UAE.